Ipsen SA

Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

03 يونيو 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen announces the launch of an employee shareholding plan

30 مايو 2024 11:15:00 بحسب Nasdaq GlobeNewswire

Annual General Meeting of Ipsen S.A. held on 28 May 2024

28 مايو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

28 مايو 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

07 مايو 2024 07:55:54 بحسب Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 مايو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen appoints Keira Driansky as EVP, President of North America

02 مايو 2024 00:30:00 بحسب Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

24 أبريل 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

22 أبريل 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen publishes its 2023 Universal Registration Document

17 أبريل 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

08 أبريل 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

02 أبريل 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07 مارس 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

15 فبراير 2024 03:00:45 بحسب Nasdaq GlobeNewswire

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

13 فبراير 2024 15:08:23 بحسب Nasdaq GlobeNewswire

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

07 فبراير 2024 23:58:00 بحسب Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 فبراير 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

22 يناير 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Ipsen – Half year statement – 2023 12 31

08 يناير 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

05 يناير 2024 11:00:00 بحسب Nasdaq GlobeNewswire